Abstract
l-Carnitine, a biomolecule able to cross the blood–brain barrier exploiting specific transporters, behaves as mono or bidentate anionic ligand for Pt(II) in the new amino complexes cis-[Pt(l-carnitine-O)2(NH3)2](BF4)2 (1), cis-[PtCl(l-carnitina-O)(NH3)2]BF4 (2), [Pt(l-carnitine-O,O′)(1,2-DACH)]BF4 (3), [Pt(l-carnitine-O)2(1,2-DACH)](BF4)2 (4), and [PtCl(l-carnitine-O)(1,2-DACH)](BF4) (5). Four complexes with DMSO have been also prepared and characterized: the synthetic intermediate [Pt(CO3)(DMSO)2] (6), [Pt(l-carnitine-O,O′)(DMSO)2]BF4 (7), cis-[Pt(l-carnitine-O)2(DMSO)2](BF4)2 (8) and cis-[PtCl(l-carnitine-O)(DMSO)2]BF4, (9).The antiproliferative activity of three representative complexes 1, 5 and 7 has been assayed against three human cancer cell lines A2780, K562 and SKOV3, and it was found comparable to that of the parent active compounds cis-[PtCl2(1,2-DACH)] and cisplatin.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
